Is histone acetylation the most important physiological function for CBP and p300?

Aging

Volumn 4, Issue 4, 2012, Pages 247-255

  Bedford, David C ^a   Brindle, Paul K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acetylation; Cancer; CBP; Chromatin; Coactivators; CREB; CREBBP; Cyclic AMP; EP300; Epigenetic; Histones; p300; Transcription

Indexed keywords

EID: 84863187331     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100453     Document Type: Article

References (86)

1. Li B, Carey M and Workman JL. The role of chromatin during transcription. Cell. 2007; 128:707-719.
2. Rando OJ and Chang HY. Genome-wide views of chromatin structure. Annual review of biochemistry. 2009; 78:245-271.
3. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W and Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009; 138:1019-1031.
4. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012; 44:251-253.
5. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, Hovestadt V, Albrecht S, Kool M, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482:226-231.
6. Faast R, Thonglairoam V, Schulz TC, Beall J, Wells JR, Taylor H, Matthaei K, Rathjen PD, Tremethick DJ and Lyons I. Histone variant H2A.Z is required for early mammalian development. Curr Biol. 2001; 11:1183-1187.
7. Changolkar LN, Costanzi C, Leu NA, Chen D, McLaughlin KJ and Pehrson JR. Developmental changes in histone macroH2A1- mediated gene regulation. Mol Cell Biol. 2007; 27:2758-2764.
8. Boulard M, Storck S, Cong R, Pinto R, Delage H and Bouvet P. Histone variant macroH2A1 deletion in mice causes femalespecific steatosis. Epigenetics Chromatin. 2010; 3:8.
9. Dai J, Hyland EM, Yuan DS, Huang H, Bader JS and Boeke JD. Probing nucleosome function: a highly versatile library of synthetic histone H3 and H4 mutants. Cell. 2008; 134:1066-1078.
10. Durrin LK, Mann RK, Kayne PS and Grunstein M. Yeast histone H4 N-terminal sequence is required for promoter activation in vivo. Cell. 1991; 65:1023-1031.
11. Thompson JS, Ling X and Grunstein M. Histone H3 amino terminus is required for telomeric and silent mating locus repression in yeast. Nature. 1994; 369:245-247.
12. Wallis JW, Rykowski M and Grunstein M. Yeast histone H2B containing large amino terminus deletions can function in vivo. Cell. 1983; 35(3 Pt 2):711-719.
13. Kayne PS, Kim UJ, Han M, Mullen JR, Yoshizaki F and Grunstein M. Extremely conserved histone H4 N terminus is dispensable for growth but essential for repressing the silent mating loci in yeast. Cell. 1988; 55:27-39.
14. Henikoff S and Shilatifard A. Histone modification: cause or cog? Trends Genet. 2011; 27:389-396.
15. Adhvaryu KK, Berge E, Tamaru H, Freitag M and Selker EU. Substitutions in the amino-terminal tail of neurospora histone H3 have varied effects on DNA methylation. PLoS Genet. 2011; 7:e1002423.
16. Parra MA, Kerr D, Fahy D, Pouchnik DJ and Wyrick JJ. Deciphering the roles of the histone H2B N-terminal domain in genome-wide transcription. Mol Cell Biol. 2006; 26:3842-3852.
17. Parra MA and Wyrick JJ. Regulation of gene transcription by the histone H2A N-terminal domain. Mol Cell Biol. 2007; 27:7641-7648.
18. Dion MF, Altschuler SJ, Wu LF and Rando OJ. Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci U S A. 2005; 102:5501-5506.
19. Martin AM, Pouchnik DJ, Walker JL and Wyrick JJ. Redundant roles for histone H3 N-terminal lysine residues in subtelomeric gene repression in Saccharomyces cerevisiae. Genetics. 2004; 167:1123-1132.
20. Jin Y, Rodriguez AM and Wyrick JJ. Genetic and genomewide analysis of simultaneous mutations in acetylated and methylated lysine residues in histone H3 in Saccharomyces cerevisiae. Genetics. 2009; 181:461-472.
21. Bedford DC, Kasper LH, Fukuyama T and Brindle PK. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics. 2010; 5:9-15.
22. Marmorstein R. Structure of histone acetyltransferases. J Mol Biol. 2001; 311:433-444.
23. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R and Cole PA. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature. 2008; 451:846-850.
24. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV and Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009; 325:834-840.
25. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J and Zhang Y. New nomenclature for chromatin-modifying enzymes. Cell. 2007; 131:633-636.
26. Dyson HJ and Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol. 2005; 6:197-208.
27. Goodman RH and Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000; 14:1553-1577.
28. Jeong H, Mason SP, Barabasi AL and Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001; 411:41-42.
29. Cantani A and Gagliesi D. Rubinstein-Taybi syndrome. Review of 732 cases and analysis of the typical traits. Eur Rev Med Pharmacol Sci. 1998; 2:81-87.
30. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RCM, Masuno M, Tommerup N, van Ommen G-JB, Goodman RH, Peters DJM and Breuning MH. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 1995; 376:348-351.
31. Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJ, Breuning MH, Hennekam RC and Peters DJ. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet. 2005; 76:572-580.
32. Kalkhoven E, Roelfsema JH, Teunissen H, den Boer A, Ariyurek Y, Zantema A, Breuning MH, Hennekam RC and Peters DJ. Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome. Hum Mol Genet. 2003; 12:441-450.
33. Murata T, Kurokawa R, Krones A, Tatsumi K, Ishii M, Taki T, Masuno M, Ohashi H, Yanagisawa M, Rosenfeld MG, Glass CK and Hayashi Y. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet. 2001; 10:1071-1076.
34. Tanaka Y, Naruse I, Hongo T, Xu M, Nakahata T, Maekawa T and Ishii S. Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mech Dev. 2000; 95:133-145.
35. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM and Eckner R. Gene dosagedependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 1998; 93:361-372.
36. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T and Ishii S. Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. Proc Natl Acad Sci U S A. 1997; 94:10215-10220.
37. Oike Y, Hata A, Mamiya T, Kaname T, Noda Y, Suzuki M, Yasue H, Nabeshima T, Araki K and Yamamura K. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet. 1999; 8:387-396.
38. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER and Barco A. Chromatin Acetylation, Memory, and LTP Are Impaired in CBP(+/-) Mice; A Model for the Cognitive Deficit in Rubinstein-Taybi Syndrome and Its Amelioration. Neuron. 2004; 42:947-959.
39. Korzus E, Rosenfeld MG and Mayford M. CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation. Neuron. 2004; 42:961-972.
40. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM and Yao TP. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 2000; 14:272-277.
41. Kasper LH, Lerach S, Wang J, Wu S, Jeevan T and Brindle PK. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. Embo J. 2010; 29:3660-3672.
42. Xu W, Fukuyama T, Ney PA, Wang D, Rehg J, Boyd K, van Deursen JM and Brindle PK. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood. 2006; 107:4407-4416.
43. Kasper LH, Fukuyama T, Biesen MA, Boussouar F, Tong C, de Pauw A, Murray PJ, van Deursen JM and Brindle PK. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol. 2006; 26:789-809.
44. Kang-Decker N, Tong C, Boussouar F, Baker DJ, Xu W, Leontovich AA, Taylor WR, Brindle PK and Van Deursen JM. Loss of CBP causes T cell lymphomagenesis in synergy with p27(Kip1) insufficiency. Cancer Cell. 2004; 5:177-189.
45. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471:189-195.
46. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, et al. Frequent mutation of histonemodifying genes in non-Hodgkin lymphoma. Nature. 2011; 476:298-303.
47. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012.
48. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui CH, Baker SD, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011; 471:235-239.
49. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011; 43:875-878.
50. Iyer NG, Ozdag H and Caldas C. p300/CBP and cancer. Oncogene. 2004; 23:4225-4231.
51. Miller RW and Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet. 1995; 56:112-115.
52. Haigis MC and Yankner BA. The aging stress response. Mol Cell. 2010; 40:333-344.
53. Zhang M, Poplawski M, Yen K, Cheng H, Bloss E, Zhu X, Patel H and Mobbs CV. Role of CBP and SATB-1 in aging, dietary restriction, and insulin-like signaling. PLoS Biol. 2009; 7:e1000245.
54. Yamauchi T, Oike Y, Kamon J, Waki H, Komeda K, Tsuchida A, Date Y, Li MX, Miki H, Akanuma Y, Nagai R, Kimura S, Saheki T, et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet. 2002; 30:221-226.
55. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S and Wondisford FE. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137:635-646.
56. Bedford DC, Kasper LH, Wang R, Chang Y, Green DR and Brindle PK. Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control. Cell Metab. 2011; 14:219-230.
57. Lin YY, Kiihl S, Suhail Y, Liu SY, Chou YH, Kuang Z, Lu JY, Khor CN, Lin CL, Bader JS, Irizarry R and Boeke JD. Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature. 2012; 482:251-255.
58. White MF. Metformin and insulin meet in a most atypical way. Cell Metab. 2009; 9:485-487.
59. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B and Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001; 413:179-183.
60. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, Takemori H and Montminy M. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005; 437:1109-1114.
61. Kasper LH, Boussouar F, Ney PA, Jackson CW, Rehg J, van Deursen JM and Brindle PK. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature. 2002; 419:738-743.
62. Zhou XY, Shibusawa N, Naik K, Porras D, Temple K, Ou H, Kaihara K, Roe MW, Brady MJ and Wondisford FE. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat Med. 2004; 10:633-637.
63. Brindle PK. 2010. Transcriptional Regulation via the cAMP Responsive Activator CREB. In: Bradshaw RA and Dennis EA, eds. Handbook of Cell Signaling (Second Edition). (San Diego: Academic Press), pp. 2077-2081.
64. Montminy M, Brindle P, Arias J, Ferreri K and Armstrong R. Regulation of somatostatin gene transcription by cyclic adenosine monophosphate. Metabolism. 1996; 45:4-7.
65. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S, Guzman E, Niessen S, Yates JR, 3rd, Takemori H, Okamoto M and Montminy M. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004; 119:61-74.
66. Conkright MD, Canettieri G, Screaton R, Guzman E, Miraglia L, Hogenesch JB and Montminy M. TORCs: transducers of regulated CREB activity. Mol Cell. 2003; 12:413-423.
67. Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, Attner MA, Cabrera SM, McDonough CB, Brindle PK, Abel T and Wood MA. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J Neurosci. 2007; 27:6128-6140.
68. Wood MA, Attner MA, Oliveira AM, Brindle PK and Abel T. A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn Mem. 2006; 13:609-617.
69. Oliveira AM, Abel T, Brindle PK and Wood MA. Differential Role for CBP and p300 CREB-Binding Domain in Motor Skill Learning. Behav Neurosci. 2006; 120:724-729.
70. Kauppi M, Murphy JM, de Graaf CA, Hyland CD, Greig KT, Metcalf D, Hilton AA, Nicola NA, Kile BT, Hilton DJ and Alexander WS. Point mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl-/- mice. Blood. 2008; 112:3148-3153.
71. Xu W, Kasper LH, Lerach S, Jeevan T and Brindle PK. Individual CREB-target genes dictate usage of distinct cAMPresponsive coactivation mechanisms. Embo J. 2007; 26:2890-2903.
72. Kasper LH and Brindle PK. Mammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia-responsive transcription. Cell Cycle. 2006; 5:142-146.
73. Kasper LH, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J, Baudino TA, Cleveland JL and Brindle PK. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. Embo J. 2005; 24:3846-3858.
74. Smolik S and Jones K. Drosophila dCBP Is Involved in Establishing the DNA Replication Checkpoint. Mol Cell Biol. 2007; 27:135-146.
75. Stauffer D, Chang B, Huang J, Dunn A and Thayer M. p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint. J Biol Chem. 2007; 282:9678-9687.
76. Fukuyama T, Kasper LH, Boussouar F, Jeevan T, van Deursen J and Brindle PK. Histone acetyltransferase CBP is vital to demarcate conventional and innate CD8+ T-cell development. Mol Cell Biol. 2009; 29:3894-3904.
77. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, Wang C, Brindle PK, Dent SY and Ge K. Distinct roles of GCN5/PCAFmediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. Embo J. 2011; 30:249-262.
78. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, Boyer LA, Young RA and Jaenisch R. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010; 107:21931-21936.
79. Zentner GE, Tesar PJ and Scacheri PC. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res. 2011; 21:1273-1283.
80. Cotney J, Leng J, Oh S, Demare LE, Reilly SK, Gerstein MB and Noonan JP. Chromatin state signatures associated with tissuespecific gene expression and enhancer activity in the embryonic limb. Genome Res. 2012.
81. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA and Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature. 2011; 470:279-283.
82. Valor LM, Pulopulos MM, Jimenez-Minchan M, Olivares R, Lutz B and Barco A. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability. J Neurosci. 2011; 31:1652-1663.
83. Hargreaves DC, Horng T and Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 2009; 138:129-145.
84. Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, Black JC, Hoffmann A, Carey M and Smale ST. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell. 2009; 138:114-128.
85. Kasper LH, Thomas MC, Zambetti GP and Brindle PK. Double null cells reveal that CBP and p300 are dispensable for p53 targets p21 and Mdm2 but variably required for target genes of other signaling pathways. Cell Cycle. 2011; 10:212-221.
86. Vo NK and Goodman RH. CBP and p300 in Transcriptional Regulation. J Biol Chem. 2001; 276:13505-13508.